Sandu Pharmaceuticals Share Price

	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024
Total Income	14.14	18.40	17.73	17.09	15.91
Total Income Growth (%)	-23.15	3.74	3.76	7.44	-8.87
Total Expenses	13.77	17.56	16.97	16.80	15.18
Total Expenses Growth (%)	-21.59	3.50	1.01	10.66	-11.02
EBIT	0.37	0.84	0.77	0.29	0.73
EBIT Growth (%)	-55.86	9.23	162.14	-59.83	83.80
Profit after Tax (PAT)	0.33	0.56	0.50	0.17	0.59
PAT Growth (%)	-42.01	13.73	197.06	-71.97	188.13
EBIT Margin (%)	2.61	4.54	4.31	1.71	4.57
Net Profit Margin (%)	2.31	3.06	2.79	0.98	3.74
Basic EPS (₹)	0.34	0.58	1.95	0.17	0.62

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	17.22	18.77	17.67	16.72	14.14
Total Income Growth (%)	-8.29	6.26	5.70	18.24	-23.15
Total Expenses	16.45	17.89	16.93	16.35	13.77
Total Expenses Growth (%)	-8.05	5.66	3.52	18.75	-21.64
EBIT	0.77	0.89	0.74	0.37	0.37
EBIT Growth (%)	-13.03	19.87	103.01	-0.98	-55.36
Profit after Tax (PAT)	0.70	0.98	0.52	0.22	0.33
PAT Growth (%)	-27.77	85.98	134.80	-31.59	-41.24
EBIT Margin (%)	4.49	4.73	4.19	2.18	2.61
Net Profit Margin (%)	4.09	5.19	2.97	1.34	2.31
Basic EPS (₹)	0.04	1.01	0.54	0.23	0.34

	FY 2025	FY 2024
Total Revenue	67.36	67.70
Total Revenue Growth (%)	-0.51	3.09
Total Expenses	65.20	65.63
Total Expenses Growth (%)	-0.66	3.42
Profit after Tax (PAT)	1.55	1.46
PAT Growth (%)	6.19	-3.90
Operating Profit Margin (%)	3.36	3.17
Net Profit Margin (%)	2.30	2.17
Basic EPS (₹)	1.60	1.51

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	70.38	67.36	67.70	65.68	65.58
Total Revenue Growth (%)	4.48	-0.51	3.08	0.14	11.25
Total Expenses	67.72	65.20	65.63	63.46	63.27
Total Expenses Growth (%)	3.86	-0.65	3.43	0.30	10.47
Profit after Tax (PAT)	1.77	1.55	1.46	1.52	1.59
PAT Growth (%)	14.02	6.05	-4.15	-4.12	45.48
Operating Profit Margin (%)	3.95	3.36	3.17	3.51	3.70
Net Profit Margin (%)	2.52	2.30	2.17	2.33	2.42
Basic EPS (₹)	1.83	1.60	1.51	1.62	1.99

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 15.29% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)

View Details

Balance Sheet

Annual	FY 2025	FY 2024
Total Assets	55.72	52.41
Total Assets Growth (%)	6.30	-3.23
Total Liabilities	13.70	11.82
Total Liabilities Growth (%)	15.90	-20.79
Total Equity	42.02	40.59
Total Equity Growth (%)	3.51	3.44
Current Ratio (x)	2.18	2.10
Total Debt to Equity (x)	0.00	0.00
Contingent Liabilities	-	-

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	55.87	55.72	52.42	54.17	49.28
Total Assets Growth (%)	0.27	6.30	-3.23	9.92	4.94
Total Liabilities	12.20	13.70	11.82	14.92	12.81
Total Liabilities Growth (%)	-10.95	15.91	-20.78	16.47	-4.90
Total Equity	43.67	42.02	40.60	39.24	36.47
Total Equity Growth (%)	3.93	3.50	3.47	7.60	8.90
Current Ratio (x)	2.43	2.18	2.10	1.84	1.99
Total Debt to Equity (x)	0.01	0.00	0.00	0.00	0.00
Contingent Liabilities	0.00	-	-	-	-

All figures in Rs Cr, unless mentioned otherwise

Insights

Undertaking New Debt
Company has outstanding debt obligations for the first time in last 5 years. (Source: Standalone Financials)

View Details

Cash Flows

Annual	FY 2025	FY 2024
Net Cash flow from Operating Activities	0.95	0.76
Net Cash used in Investing Activities	-0.19	-1.31
Net Cash flow from Financing Activities	-0.46	-0.72
Net Cash Flow	0.30	-1.27
Closing Cash & Cash Equivalent	1.30	1.00
Closing Cash & Cash Equivalent Growth (%)	29.86	-55.87
Total Debt/ CFO (x)	0.00	0.00

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	6.12	0.95	0.76	0.22	0.95
Net Cash used in Investing Activities	-0.57	-0.18	-1.31	0.53	-5.47
Net Cash flow from Financing Activities	-0.94	-0.46	-0.72	0.58	0.93
Net Cash Flow	4.60	0.31	-1.27	1.33	-3.59
Closing Cash & Cash Equivalent	5.91	1.30	1.00	2.27	0.94
Closing Cash & Cash Equivalent Growth (%)	353.08	30.98	-56.06	141.37	-79.27
Total Debt/ CFO (x)	0.07	0.00	0.00	0.00	0.00

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 0.95 cr is 0.61 times compared to the reported net profit of Rs 1.55 cr. (Source: Consolidated Financials)
Increase in Cash from Investing
Company has used Rs 0.57 cr for investing activities which is an YoY increase of 216.7%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2025	FY 2024
Return on Equity (%)	3.69	3.59
Return on Capital Employed (%)	5.18	5.11
Return on Assets (%)	2.78	2.78
Interest Coverage Ratio (x)	28.39	43.10
Asset Turnover Ratio (x)	1.24	1.26
Price to Earnings (x)	30.58	38.02
Price to Book (x)	1.13	1.37
EV/EBITDA (x)	15.24	19.95
EBITDA Margin (%)	4.36	4.04

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	4.04	3.68	3.59	3.88	4.35
Return on Capital Employed (%)	6.08	5.17	5.11	5.70	6.48
Return on Assets (%)	3.16	2.77	2.78	2.81	3.22
Interest Coverage Ratio (x)	30.73	28.36	43.08	35.38	26.88
Asset Turnover Ratio (x)	1.25	1.24	1.26	1.26	1.36
Price to Earnings (x)	16.72	30.58	38.02	33.11	39.06
Price to Book (x)	0.68	1.13	1.37	1.29	1.70
EV/EBITDA (x)	6.69	15.25	19.95	17.09	19.55
EBITDA Margin (%)	4.92	4.36	4.04	4.30	4.51

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Sandu Pharma	16.47	0.92	4.04	6.08	3.16	2.31	3.95	2.52	1.83	2.43	0.01	0.07
Bacil Pharma	44.02	2.38	6.26	3.99	5.67	119.14	0.00	0.00	1.11	0.68	0.00	0.00
Vivimed Labs	-1.44	-1.44	0.00	-5.63	-3.47	-20.15	-24.85	-27.48	-3.85	0.80	-5.14	-214.92
Mangalam Drugs	-1.01	0.44	-43.08	-27.33	-14.09	-14.37	-13.94	-19.12	-28.05	0.79	1.02	25.25
Vista Pharma	-3.66	1.21	-33.09	-39.15	-21.89	58.95	-278.73	-223.37	-1.96	0.92	0.27	-2.27
Add More

Annual Ratios (%)

Choose from Peers

Roopa Ind
Medi-Caps Ltd
Welcure Drugs
Parmax Pharma
Gujarat Terce

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Sandu Pharma Stock Performance	-0.19	11.24	8.58	12.60	-27.31	-26.13	2.40
Bacil Pharma Stock Performance	3.64	-27.72	-30.11	-13.21	0.00	487.73	0.00
Vivimed Labs Stock Performance	5.00	-6.45	-16.12	-24.63	0.00	0.00	-78.48
Mangalam Drugs Stock Performance	-1.08	-5.68	-1.01	-11.53	-63.85	-73.68	-79.16
Vista Pharma Stock Performance	3.30	-0.97	-0.14	-5.28	-35.26	-18.04	-41.48
Add More

Category	No. of Shares	Percentage
Promoters	36,50,548	37.79 %
Pledge	0	0.00 %
Others	60,10,442	62.21 %

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	37.79	37.79	42.90	42.90
Pledge	0.00	0.00	0.00	0.00
FII	0.00	0.00	0.00	0.00
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	62.21	62.21	57.10	57.10

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Final
10%
May 05, 2026
Board Meeting
Audited Results & Final Dividend
Apr 27, 2026
Board Meeting
Quarterly Results
Jan 27, 2026

Board Meetings

Announced on	Meeting on
Apr 27, 2026	May 05, 2026
Audited Results & Final Dividend
Jan 27, 2026	Feb 06, 2026
Quarterly Results
Nov 06, 2025	Nov 12, 2025
Quarterly Results
Oct 06, 2025	Oct 14, 2025
Others
Aug 04, 2025	Aug 13, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 28, 2025 Sep 18, 2025 8%
Aug 14, 2024 Sep 19, 2024 8%
Aug 14, 2023 Sep 18, 2023 7%
Aug 12, 2022 Sep 23, 2022 7%
May 05, 2026 - 10%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available

Announced on	Ex-Date	Dividend%
May 28, 2025	Sep 18, 2025	8%
Aug 14, 2024	Sep 19, 2024	8%
Aug 14, 2023	Sep 18, 2023	7%
Aug 12, 2022	Sep 23, 2022	7%
May 05, 2026	-	10%

AGM/EGM Meetings

Announced on	Meeting on
Oct 17, 2025	Nov 20, 2025
-
Aug 13, 2025	Sep 30, 2025
-
Aug 14, 2024	Sep 30, 2024
Rs.0.8000 per share(8%)Final Dividend & A.G.M.
Aug 14, 2023	Sep 30, 2023
Rs.0.7500 per share(7.5%)Final Dividend & A.G.M.
Sep 01, 2020	Sep 30, 2020
Book closure from Sep 24, 2020 to Sep 30, 2020

About Sandu Pharma

Sandu Pharmaceuticals Ltd., incorporated in the year 1985, is a Small Cap company (having a market cap of Rs 39.97 Crore) operating in Pharmaceuticals sector.

Sandu Pharmaceuticals Ltd. key Products/Revenue Segments include Ayurvedic Products for the year ending 31-Mar-2025.

For the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 14.14 Crore, down 23.15 % from last quarter Total Income of Rs 18.40 Crore and down 11.11 % from last year same quarter Total Income of Rs 15.91 Crore. Company has reported net profit after tax of Rs .33 Crore in latest quarter.

The company’s top management includes Mr.Umesh B Sandu, Mr.Shashank B Sandu, Mr.Ajit R Kantak, Mr.Balram Viswanathan, Mr.Jayshree Sandu, Mr.Vijay Kottapalli, Mr.Vijay Kajarekar, Ms.Pratika Mhambray. Company has Dileep and Prithvi as its auditors. As on 31-03-2026, the company has a total of .97 Crore shares outstanding.

Sandu Pharma Share Price Today is Rs. 41.37. On previous day, the Sandu Pharma Share Price (NSE) closed at Rs. 41.51, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 37.79% of the stake in Sandu Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Sandu Pharma stocks was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. Out of the total DII holdings in Sandu Pharma shares 0.0% was held by mutual funds. The rest including public held is 0.0%. Sandu Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Sandu Pharma Dividend: Ever since 1985, Sandu Pharma dividends has been paid out around 8 times. As on 29 Jun, 2026, 03:40 PM IST, The overall dividend yield for Sandu Pharma stands at 2.42%. The last dividend paid was on September 18, 2025 (Rs. 0.8). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 2.51.

Sandu Pharma Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 17.22 Cr. of sales and 8.29% of quarterly net loss, there have been multiple ups and downs in the Sandu Pharma stock prices in the past few weeks. For example, Sandu Pharma stock price on 19th of June 2026 was around Rs. 42.22. Sandu Pharma share price now stands at an average of Rs. 41.37. Judging by last week's performance, stock is in down trend.

Sandu Pharma has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Sandu Pharma share.

Historical Prices and Performance:
Sandu Pharma, incorporated in 1985 is a Small Cap company (with a market cap of Rs. 40.0) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Sandu Pharma stock was 4.04%, 3.69%, 3.59%, 3.87% and 4.35% respectively.
The Sandu Pharma share gave a 3 year return of -27.33% as compared to Nifty 50 which gave a return of 28.88%.
Sandu Pharma announced 8.0% final dividend on September 18, 2025.

Key Metrics:
PE Ratio of Sandu Pharma is 16.48
Prices/Sales Ratio of Sandu Pharma is 0.42
Price/Book Ratio of Sandu Pharma is 0.92

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at 16.48 and 0.92 respectively.

Leadership of Sandu Pharma :
Pratika Mhambray is Co. Secretary & Compl. Officer
Vijay Kajarekar is Chief Financial Officer
Umesh B Sandu is Executive Director
Shashank B Sandu is Non Exe.Non Ind.Director
Balram Viswanathan is Ind. Non-Executive Director
Ajit R Kantak is Ind. Non-Executive Director
Jayshree Sandu is Ind. Non-Executive Director
Vijay Kottapalli is Ind. Non-Executive Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

Plot, No. 25, 26, 29 & 30,Pilerne Industrial Estate,Goa, Goa - 403511

Contact

corp.sec@sandu.in

http://www.sandu.in

PE Ratio(x)	16.47
EPS - TTM(₹)	2.51
MCap(₹ Cr.)	39.97
MCap Rank	156
PB Ratio(x)	0.92
Div Yield(%)	2.42
Face Value(₹)	10.00
52W High(₹)	58.28
52W Low(₹)	30.00
MCap/Sales	0.42
Beta(1 Month)	4.35
BV/Share(₹)	45.21

1 Day	-0.19%
1 Month	-1.5%
3 Months	24.01%
1 Year	-17.23%
3 Years	-26.78%
5 Years	-28.86%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Sandu Pharmaceuticals Share Price

Key Metrics

Sandu Pharma share price insights

Sandu Pharma Share Price Returns

Sandu Pharma Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Sandu Pharma Top Searches

Corporate Actions

About Sandu Pharma

Executive Leadership

Auditors

FAQs about Sandu Pharma share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News